Skip to Content
Merck
CN

SML2840

AZD2066

≥98% (HPLC)

Synonym(s):

4-[5-[(1R)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine, AZD 2066

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C19H16ClN5O2
CAS Number:
934282-55-0
Molecular Weight:
381.82
UNSPSC Code:
12352200
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

AZD2066, ≥98% (HPLC)

SMILES string

Clc1cc(ccc1)c2[o]nc(c2)[C@H](Oc3[n](c(nn3)c4ccncc4)C)C

InChI

1S/C19H16ClN5O2/c1-12(16-11-17(27-24-16)14-4-3-5-15(20)10-14)26-19-23-22-18(25(19)2)13-6-8-21-9-7-13/h3-12H,1-2H3/t12-/m1/s1

InChI key

SXWHYTICXCLKDG-GFCCVEGCSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

Quality Level

100

Biochem/physiol Actions

AZD2066 is an orally bioavailable, brain penetrant, selective and potent negative allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGlu5). AZD2066 exhibited satisfactory efficacy in patients suffering from neuropathic pain with mechanical hypersensitivity.
orally bioavailable, brain penetrant, selective and potent negative allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGlu5)

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000119918
0000119919
0000110073

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Brittany A Jaso et al.
Current neuropharmacology, 15(1), 57-70 (2016-03-22)
Current pharmacotherapies for major depressive disorder (MDD) have a distinct lag of onset that can prolong distress and impairment for patients, and realworld effectiveness trials further suggest that antidepressant efficacy is limited in many patients. All currently approved antidepressant medications
Matts Kågedal et al.
NeuroImage, 82, 160-169 (2013-05-15)
AZD2066 is a new chemical entity pharmacologically characterized as a selective, negative allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGluR5). Antagonism of mGluR5 has been implicated in relation to various diseases such as anxiety, depression, and pain disorders.
Michael D B Swedberg et al.
The Journal of pharmacology and experimental therapeutics, 350(2), 212-222 (2014-05-31)
The metabotropic glutamate receptor 5 (mGluR5) antagonists fenobam, MPEP (2-methyl-6-(phenylethynyl)pyridine), and MTEP (3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine) were previously shown to not cause N-methyl-D-aspartate antagonist-like psychoactive effects in phencyclidine (PCP) drug discrimination studies, but to cause MTEP-like discrimination in rats, suggesting that the psychoactive

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service